Filgrastim biosimilar - Biocon/Mylan

Drug Profile

Filgrastim biosimilar - Biocon/Mylan

Alternative Names: Nufil; Recombinant human granulocyte colony stimulating factor - Biocon

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocon
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Neutropenia in European Union (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Neutropenia in USA (IV, Injection)
  • 14 Oct 2013 Clinical trials in Neutropenia in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top